Author Archives: Steve Walker

Alnylam soars on RNAi success as Phase 3 patisiran study hits all goals; market overreacts as pipeline unproven and competition lurks.

The News: Alnylam Pharmaceuticals Inc.’s (Cambridge MA) RNAi-based drug that targets a rare genetic disease cleared a key study, in a breakthrough for the new class of medicines that works… Read more »

McConnell scraps Graham-Cassidy bill; but be mindful of Yogi Berra’s quip back in 1973.

The Latest: Senate Republican leaders on Tuesday (September 26, 2017) officially pulled the plug on the latest plan to repeal the Affordable Care Act, abandoning a planned vote on the… Read more »

Zai Lab’s U.S. IPO marks another white-hot Chinese offering that begs the question: why are these Asian offerings so special?

The News: Shang­hai-based biotech Zai Lab Ltd. raised $150 mil­lion from its up­sized IPO last Wednes­day (September 20, 2017), sell­ing 8.3 mil­lion shares at $18 each. After trad­ing began, the… Read more »

Weekly stock roundup: Marinus, McKesson are Buys, but not for everyone.

Marinus Pharmaceuticals Inc. (Nasdaq:MRNS) was among the top advancing issues last week, soaring 31% to $4.10. Investors pounced on shares after the Radnor, PA-based drugmaker announced that top-line data from… Read more »

Latest ACA repeal bill returns for one more Senate audition; will McConnell, other GOP leadership put it to a vote?

The News: Powerful healthcare groups continued to denounce the Graham-Cassidy bill Wednesday (September 20, 2017), including AARP and the American Hospital Association, both of which urged a “no” vote. But… Read more »

Amgen, Allergan get nod for Avastin biosim; FDA’s Gottlieb making good on vow to hasten generic approvals, catch the EU.

The News: Amgen Inc. (Thousand Oaks CA) and Allergan PLC (Dublin IRL) said Thursday (September 14, 2017) that the Food and Drug Administration has approved their biosimilar version of Roche… Read more »

GOP Sen. Alexander’s plucky, bipartisan bill to fix Obamacare headed to Senate vote this week; does this dark horse have a chance in such a crowded field?

The News: The month of September has been blitzed with healthcare bills. Last week alone, Democrat and Republican senators introduced both a single-payer plan and an Affordable Care Act (ACA) repeal and replacement… Read more »

Slumbering giant Lilly to cut more jobs, take a $1.2-billion hit to bolster R&D pipeline.

The News: Eli Lilly & Co. (Indianapolis IN) last week said it would lay off about 8% of its employees as the drugmaker, which has suffered setbacks over the past… Read more »

Stock round-up features superb week for Insmed and NewLink; not so much for Cellectis.

Insmed Inc. (Nasdaq:INSM) led advancing issues, more than doubling (+146%) over the week, to $30.25 as of Tuesday morning, September 12. The explosion began after the company announced that its… Read more »